Both semaglutide and tirzepatide cause similar GI side effects, but the rates differ. SURMOUNT-5 reported comparable tolerability between the two drugs. Nausea, diarrhea, and vomiting are most common during dose titration and typically resolve within 2-4 weeks at each dose level. Here's the side-by-side data from clinical trials.
Side effects are the number one reason people stop GLP-1 treatment. Understanding what to expect — and how semaglutide and tirzepatide compare — helps you prepare, manage, and stick with treatment through the adjustment period.
GI Side Effects: Head-to-Head
| Side Effect | Semaglutide (Wegovy) | Tirzepatide (Zepbound) |
|---|---|---|
| Nausea | 40-44% | 24-33% (lower) ✓ |
| Diarrhea | 30% | 18-25% |
| Vomiting | 24% | 10-13% (lower) ✓ |
| Constipation | 24% | 17-23% |
| Abdominal pain | 20% | 14-18% |
| Injection site reactions | 3-5% | 3-7% |
| Fatigue | 11% | 9-12% |
| Headache | 14% | 12-16% |
Key takeaway: Tirzepatide tends to have lower nausea and vomiting rates than semaglutide in clinical trials, despite producing more weight loss. Some researchers attribute this to the GIP receptor component, which may provide a "buffering" effect on GI symptoms. However, individual responses vary significantly.
When Side Effects Peak
GI side effects follow a predictable pattern for both medications:
Weeks 1-2 of each dose level: Side effects peak. Nausea is worst on days 2-4 after your injection. Most patients describe it as mild to moderate — uncomfortable but not debilitating.
Weeks 3-4: Your body adapts. Nausea decreases significantly. Appetite suppression stabilizes.
Dose increase: Side effects typically return at a lower intensity when you increase dose, then resolve again over 1-2 weeks.
Therapeutic dose (steady state): Most patients at therapeutic dose for 4+ weeks report minimal GI side effects. The titration phase is temporary.
Serious Side Effects (Rare but Important)
| Serious Side Effect | Semaglutide | Tirzepatide | Action |
|---|---|---|---|
| Pancreatitis | Rare (<1%) | Rare (<1%) | Stop medication, seek care immediately |
| Gallbladder disease | 1-3% | 1-2% | Report to provider; may need evaluation |
| Thyroid C-cell tumors | Black box warning* | Black box warning* | Contraindicated with MTC history |
| Kidney injury | Rare (dehydration-related) | Rare (dehydration-related) | Stay hydrated; report changes in urination |
| Allergic reaction | Rare | Rare | Stop medication, seek care immediately |
*The thyroid C-cell tumor warning is based on rodent studies at doses much higher than human therapeutic doses. No causal link has been established in humans, but both medications are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Managing Common Side Effects
Nausea
Eat smaller meals throughout the day instead of large ones. Avoid fatty, greasy, or heavy foods during the first week after dose increases. Ginger tea or ginger chews may provide mild relief. Stay hydrated. If nausea persists beyond 2 weeks at any dose level, contact your provider — they may slow your titration schedule.
Constipation
GLP-1 medications slow gastric emptying, which can cause constipation. Increase fiber intake gradually, stay well-hydrated (aim for 64+ oz of water daily), and consider a stool softener if dietary changes aren't sufficient. Regular physical activity also helps.
Fatigue
Some patients report fatigue during the first few weeks of treatment or after dose increases. This typically resolves as your body adjusts. If persistent fatigue develops after weeks on a stable dose, tell your provider — it may warrant lab work to check thyroid function or other factors.
Side Effects and the "Worth It" Question
Most patients describe GLP-1 side effects as "uncomfortable but manageable" during titration, and "minimal to none" once at a stable therapeutic dose. The side effect profile is considerably milder than most weight loss medications historically available.
The important context: these medications produce 15-20% body weight loss on average, reduce cardiovascular risk, improve metabolic markers, and in many cases reverse type 2 diabetes. Temporary GI discomfort during a 3-5 month titration phase is a meaningful trade-off for most patients.
Start With Guided Titration Support
MEDVi provides structured dose management and proactive side effect support throughout your treatment.
Check MEDVi Pricing →Affiliate link · Prices verified March 2026
If you're experiencing side effects that concern you, talk to your provider before stopping medication. Many side effects can be managed with slower titration, dietary adjustments, or supportive treatments.